Biogen, UCB report Phase IIb miss for lupus candidate dapirolizumab

Biogen Inc. (NASDAQ:BIIB) and UCB S.A. (Euronext:UCB) reported top-line data showing dapirolizumab pegol missed the primary endpoint in a Phase IIb trial to treat moderate to severe active systemic lupus erythematosus (SLE) in patients receiving standard of care (SOC). Dapirolizumab failed to show a dose response at week 24 vs. placebo (p=0.06) on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA).

The double-blind, international trial enrolled 182 patients. Biogen and UCB are co-developing the anti-CD40 ligand (CD40L) Fab antibody for SLE...